Expression of oncogenic H-Ras in 23A2 myoblasts (A2:H-Ras cells) is sucient to induce both a transformed phenotype and a dierentiation-defective phenotype. Because oncogenic Ras is known to induce the secretion of several dierent growth factors involved in maintaining the transformed phenotype of both ®broblast and epithelial cells, we explored the possibility that expression of oncogenic Ras in 23A2 myoblasts might lead to the secretion of a factor which inhibits dierentiation. The dierentiation of 23A2 myoblasts was inhibited (i) by coculture with an equal number of A2:H-Ras cells, (ii) by culture with an equal number of A2:H-Ras cells in the same tissue culture medium on an insert which allowed equilibration of molecules smaller than 1 micron, and (iii) by culture in media previously conditioned by A2:H-Ras cells. Similar results were obtained when 23A2 myoblasts expressing oncogenic NRas were substituted for A2:H-Ras cells in each assay. No inhibition of dierentiation was observed, however, when dierentiation-defective E1A-expressing 23A2 cells or C3H10T1/2 ®broblasts were substituted for A2:HRas cells. The dierentiation inhibitor(s) in media conditioned by A2:H-Ras cells is heat stable, larger than 3 kD, and sensitive to the non-speci®c growth factor antagonist, suramin. Western analyses failed to detect either FGF-2 or TGFb (the known inhibitors of myoblast dierentiation) in media conditioned by A2:H-Ras cells. Furthermore, while FGF-2 is a potent activator of MAP kinase and TGFb is a potent inhibitor of mink lung epithelial cell (CCL64) growth, conditioned media from A2:H-Ras cells does not activate MAP kinase and does not inhibit the growth of CCL64 cells. These results indicate that expression of oncogenic Ras induces the secretion of a novel inhibitor of skeletal myoblast dierentiation. Furthermore, these results are the ®rst to implicate an autocrine/paracrine mechanism in the inhibition of dierentiation by oncogenic Ras.
Introduction
Cancer develops when a normal cell acquires the ability to circumvent a multitude of growth constraints. This complex process begins with the mutation of key regulatory genes (initiation) followed by clonal expansion of the initiated cell (promotion) and ®nally acquisition of the ability to invade surrounding tissus and disseminate to other organs (progression). Oncogenic mutation of ras genes has been implicated as a causative event throughout the process of tumorigenesis (Weyman and Stacey, 1996) . Autocrine secretion of growth factors assists tumor cells in escaping normal growth constraints (Sporn and Roberts, (1985) . Expression of oncogenic Ras correlates with the secretion of both growth (Pironin et al., 1992; Dawson et al., 1995; Berkowitz et al., 1996) and angiogenic factors (Rak et al., 1995) . The mammalian ras family consists of three genes, Ha-, K-and N-, which each encode 21 kD membrane tethered proteins (Lowy and Willumsen, 1993) . The binding of growth factors to their cognate receptors initiates a series of well characterized events resulting in the activation of Ras proteins via the stimulated exchange of GDP for GTP (Feig, 1993; Burgering and Bos, 1995) . p120GAP-or Neuro®bromin-mediated stimulation of Ras' intrinsic GTPase activity returns Ras to its inactive GDP-bound conformation (Hall, 1990; McCormick, 1995) . Oncogenic Ras is insensitive to negative regulation by GAP and Neuro®bromin (Lowy and Willumsen, 1993) .
Cancer is commonly considered a disease of arrested tissue dierentiation and tumors are classi®ed as benign or malignant based on the degree of differentiation abnormality. Dierentiation is a stepwise process during which cells acquire the speci®c characteristics of the mature terminally dierentiated phenotype. As cells become more mature, their proliferative potential becomes more restricted. Proliferation and terminal dierentiation are ultimately mutually exclusive events. As such, the aggressiveness of a given tumor is closely correlated with the degree of dierentiation of the initiated cell (Visscher and Heppner, 1996) . Skeletal muscle is one of the most tractable model systems in which to study the pathways regulating proliferation and dierentiation. Committed myoblasts undergoing in vitro dierentiation exit the cell cycle, express a battery of muscle speci®c-genes, and fuse into multinucleated myotubes (Rudnicki and Jaenisch, 1995; Andres and Walsh, 1996) . Skeletal muscle differentiation is positively mediated by activation of the muscle regulatory factor (MRF) family of transcription factors (Ludolph and Konieczny, 1995) . The signaling pathways utilized to activate the MRFs, however, have not been identi®ed. Clues have come mostly from studying the signaling pathways utilized by molecules which inhibit dierentiation. The actions of the MRFs, and consequently skeletal myoblast dierentiation, are abrogated by culturing myoblasts in fetal serum, FGF2, TGFb, by expression of oncogenes such as Src, Ras, Myc, Fos or Jun or by expression of the E1A protein (Schneider and Olson, 1988; Florini et al., 1991; Olson, 1992; Alema and Tato, 1994) .
Expression of oncogenic Ras in skeletal myoblasts results in both a transformed and dierentiationdefective phenotype Weyman et al., 1997) . Skeletal myoblasts are thus an intriguing model system in which to study Ras signaling. Because expression of oncogenic Ras has been linked to the secretion of a variety of growth factors and because serum growth factors, FGF-2 and TBFb inhibit the dierentiation of skeletal myoblasts, we explored the possibility that expression of oncogenic Ras in 23A2 myoblasts might result in the secretion of a factor capable of inhibiting myoblast dierentiation. In this study, we show that cells expressing either oncogenic H-Ras or oncogenic N-Ras secrete a factor(s) which inhibits the dierentiation of 23A2 myoblasts. This inhibitory activity is heat stable, sensitive to a general growth factor antagonist, and can be concentrated by centrifugation through a membrane which retains molecules or complexes larger than 3 kD. We further demonstrate that this activity is biochemically and immunologically distinct from the known inhibitors of myoblasts dierentiation.
Results

Oncogenic H-Ras expressing 23A2 myoblasts secrete an inhibitor of skeletal myoblast dierentiation
The in vitro dierentiation of skeletal myoblasts is commonly monitored biochemically by the expression of the muscle speci®c protein myosin heavy chain (MHC) and morphologically by the fusion of individual myoblasts into multinucleated myotubes. Culturing 23A2 myoblasts in growth medium (GM: BME/10% FBS) prevents their dierentiation while culturing 23A2 myoblasts in dierentiation medium (DM: BME/0% FBS) induces their dierentiation (Weyman et al., 1997) . 23A2 myoblasts expressing oncogenic H-Ras (A2:H-Ras) are dierentiationdefective and do not express MHC or fuse into multinucleated myotubes even when cultured in DM Weyman et al., 1997) . Three distinct approaches were used to determine if expression of oncogenic Ras resulted in the secretion of a factor capable of inhibiting skeletal myoblast differentiation. In each assay, 10T ®broblasts (from which 23A2 myoblasts are derived) (Konieczny and Emerson, 1984) and 23A2 myoblasts rendered dierentiationdefective by expression of the adenovirus E1A protein (A2:E1A) (Enkeman et al., 1990) are substituted for the A2:H-Ras cells to demonstrate that secretion of an inhibitory factor is not common to all cells incapable of terminally dierentiating into skeletal myo®bers. Firstly, 23A2 myoblasts were cocultured in DM with an equal number of oncogenic H-Ras expressing 23A2 cells (A2:H-Ras). Culturing 23A2 myoblasts in DM for 48 h induces their dierentiation as monitored by the expression of MHC (Weyman et al., 1997) and Figure  1 ) and by fusion into myotubes (Weyman et al., 1997) . Coculturing 23A2 myoblasts in DM for 48 h with A2:H-Ras cells, however, abrogates their ability to dierentiate as monitored by the lack of MHC expression (detected either by Western blot analysis (Figure 1 ) or by immunostaining of ®xed cells, data not shown, (d.n.s.)) and by the lack of fusion into myotubes (d.n.s.). Coculturing 23A2 myoblasts with either 10T1/2 ®broblasts or A2:E1A cells does not inhibit their dierentiation (Figure 1) .
Secondly, 23A2 myoblasts were cultured with an equal number of A2:H-Ras cells plated on an insert which allows the equilibration of molecules greater than 1 mcron. After 48 h in DM the 23A2 myoblasts were immunostained for MHC. Culturing 23A2 myoblasts in DM with an insert containing no cells permits their dierentiation as detected by the expression of MHC and the fusion of individual cells into multinucleated myotubes (Figure 2) . Similarly, 23A2 myoblasts cultured in DM with inserts containing 10T1/2 or A2:E1A cells still express MHC and fuse into multinucleated myotubes (Figure 2 ). Culturing 23A2 myoblasts in DM with an insert containing an equal number of A2:H-Ras cells, however, diminishes their ability to dierentiate to nearly undetectable levels ( Figure 2 ). This result rules out the possibility that the dierentiation inhibitor resides in, or is tethered to, the plasma membrane of the A2:H-Ras cells. Figure 2 MHC immunostain of 23A2 myoblasts cultured with inserts containing A2:H-Ras, A2:E1A or 10T1/2 cells. A2:H-Ras, A2:E1A or 10T1/2 cells were plated on inserts which allow the equilibration of molecules greater than 1 mcron. These inserts were cultured with an equal number of 23A2 myoblasts. After 48 h in DM, the 23A2 myoblasts were immunochemically stained for MHC as described in Materials and methods Finally, conditioned media was generated by incubating equal numbers of 23A2, A2:H-Ras, A2:E1A, or 10T1/2 cells to DM for 48 h. 23A2 myoblasts cultured with conditioned DM from 23A2, A2:E1A or 10T1/2 cells for 48 h expressed MHC to levels comparable to 23A2 myoblasts cultured in naive DM (Figure 3 ). Culturing 23A2 myoblasts with DM conditioned by A2:H-Ras cells, however, severely impairs their expression of MHC ( Figure 3 ) and their fusion into myotubes (d.n.s.). Culturing cells in the A2:H-Ras conditioned DM does not aect the detection of luciferase expressed from a transiently transfected vector (d.n.s.) suggesting that abrogation of MHC expression does not result from the presence of a non-speci®c inhibitor of transcription or translation.
MHC
The secreted dierentiation inhibitor is heat stable, suramin sensitive and retained by a 3 kD cuto membrane Skeletal myoblast dierentiation is inhibited by several peptide growth factors (Vaidya et al., 1989; Florini et al., 1991; Olson, 1992) . A common property of small peptide growth factors is their resistance to heat denaturation. Inhibition of MHC expression could be observed by culturing 23A2 myoblasts for 2 days in DM that had been conditioned by A2H-Ras cells for either 24 or 48 h (Figure 4a ). Boiling the conditioned DM for 30 min prior to the transfer to 23A2 myoblasts does not destroy the inhibitory activity and permit expression of MHC ( Figure 4a ). 23A2 myoblasts cultured in naive DM which has been boiled identically had no aect on their abiity to express MHC or fuse (d.n.s.). The actions of many peptide growth factors are abrogated by the non-speci®c antagonist, suramin (Schrell et al., 1995) . 23A2 myoblasts cultured in DM supplemented with suramin express MHC to the same level as cells cultured without suramin (Figure 4b ). Supplementing the A2:H-Ras conditioned DM with suramin, however, completely negates the inhibitory activity and permits expression of MHC to levels found in control myoblasts ( Figure 4b ). In support of the hypothesis that a peptide growth factor was responsible for the inhibition of dierentiation, the conditioned media was concentrated 10-fold using a 3 kD cuto membrane. The starting material could be diluted 10-fold (500 ml in 5 ml of naive DM) and still function to inhibit the expression of MHC (Figure 4c ). After concentrating 15 ml of starting material to 1.5 ml (3 kD RET), the 3 kD RET could be diluted 100-fold (50 ml in 5 ml) and still repress the expression of MHC (Figure 4c ). 23A2 myoblasts cultured in the media which¯owed through the 3 kD-cuto membrane (3 kD FT) expressed MHC at levels comparable to 23A2 myoblasts in naive DM (Figure 4c ).
Neither FGF-2 nor TGFb is immunologically detected in A2:H-Ras conditioned media FGF-2 and TGFb are the peptide growth factors known to inhibit the dierentiation of skeletal myoblasts (Vaidya et al., 1989; Florini et al., 1991; Olson, 1992) . Western analyses using antibodies speci®c for FGF-2 or TGFb were peformed to determine if either of these growth factors are Characterization of the activity in A2:H-Ras conditioned media which inhibits dierentiation. (a) Equal numbers of 23A2 myoblasts were plated and then switched to DM, the indicated dilution of DM which had been previously conditioned for 24 or 48 h by A2:H-Ras cells, or conditioned DM which had been boiled for 30 min. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure 1 . Shown are results from one experiment which are representative of two independent experiments. (b) Equal numbers of 23A2 myoblasts were plated and then switched to DM, the indicated dilution of DM which had been previously conditioned for 48 h by A2:H-Ras cells, or conditioned DM supplemnted with 100 mM suramin. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure  1 . (c) Equal numbers of 23A2 myoblasts were plated and then switched to DM, the indicated volume of DM which had been previously conditioned for 48 h by A2:H-Ras cells (starting), or the indicated volumes of A2:H-Ras conditioned media which was either retained (3 kD RET) or not retained (3 kD FT) by a membrane which allows the passage of molecules smaller than 3 kD. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure 1 . Shown are results from one experiment which are indicative of three independent experiments secreted by A2:H-Ras cells. The minimum dose of FGF-2 or TGFb required for the inhibition of 23A2 myoblast dierentiation is 10 ng/ml (50 ng/100 mm plate) (manuscript submitted) and 2 ng/ml (10 ng/ 100 mm plate) (d.n.s.), respectively. For this approach to yield interpretable data, the immunological detection of FGF-2 or TGFb must be sensitive enough to detect 50 ng and 10 ng, respectively. Recombinant FGF-2 or TGFb, at amounts which are 20% of the minimum required to inhibit 23A2 myoblast differentiation (2 and 10 ng, respectively), are easily detected with these antibodies (Figure 5) . A 3 kD concentrate of A2:H-Ras conditioned DM, which was sucient to prevent 23A2 myoblast dierentiation (Figure 4c) , was separated by SDS ± PAGE (15%) and subjected to Western analyses using antibodies speci®c for FGF2 or TGFb. No immunoreactive bands were visualized ( Figure 5 ).
A2:H-Ras conditioned media does not mimic the actions of FGF-2, IGF-1 or TGFb
We have recently shown that IGF-1 is comparable to FGF-2 in its ability to inhibit the dierentiation of 23A2 myoblasts and that both FGF-2 and IGF-1 are potent activators of MAPK in 23A2 myoblasts (manuscript submitted). We, therefore, tested the ability of the A2:H-Ras conditioned DM to activate MAPK. Neither treatment of 23A2 myoblasts with DM conditioned by 23A2 nor A2:H-Ras cells resulted in an increase in MAPK activity comparable to that observed when 23A2 myoblasts were treated with the minimum dose of FGF-2 or IGF-1 (10 ng/ml, 50 ng/ 100 mm plate) required for the inhibition of differentiation (Figure 6a ). This is not due to the inability of FGF-2 or IGF-1 to activate MAPK in the presence of conditioned DM (d.n.s.). PD 098059 (Alessi et al., 1995) , the selective chemical inhibitor of MEK (the immediate upstream activator of MAPK) was added to the A2:H-Ras conditioned DM prior to transfer to the 23A2 myoblasts to further rule out a requirement for the activation of MEK and MAPK in the inhibition of dierentiation by the conditioned DM. Supplementing naive DM with PD 098059 did not aect the expression of MHC (Weyman et al., 1997 and Figure 6b ) and did not restore a myogenic phenotype to 23A2 myoblasts cultured in the A2:HRas conditioned media (Figure 6b) . Furthermore, while treatment of 23A2 myoblasts with either FGF-2 or IGF-1 inducs a slight increase in the incorporation of thymidine into newly synthesized DNA, treatment of 23A2 myoblasts with A2:H-Ras conditioned DM does not (d.n.s.). The ®nding that A2:HRas conditioned DM blocks 23A2 myoblast differentiation without inducing proliferation is not surprising since it is well documented that the inhibition of dierentiation by growth factors or by oncogenic Ras does not rely on their mitogenic potential Olson et al., 1987; Payne et al., 1987; Gossett et al., 1988; Lathrop et al., 1985; Rosenthal and Cheng, 1995; Weyman et al., 1997) .
TGFb is a well characterized growth inhibitor of CCL64 epithelial cells. We, therefore, tested the ability of the A2:H-Ras conditioned media to inhibit the growth of CCL64 cells. Neither treatment of CCL64 cells with media conditioned by 23A2 or A2:H-Ras cells inhibited their ability to incorporate thymidine into newly synthesized DNA (Figure 7) . TGFb, at the minimum dose (2 ng/ml, 10 ng/100 mm plate) required for the inhibition of dierentiation, eciently blocked the incorporation of thymidine into CCL64 cell DNA (Figure 7 ). The inhibition 23A2 myoblast dierentiation by A2:HRas conditioned media does not rely on the activation of MAPK.
(a) Equal numbers of 23A2 (A2) myoblasts were plated and then switched to DM for 3 h prior to stimulation with 10 ng/ml FGF-2 or IGF-1 or undiluted A2 or A2:H-Ras conditioned media. After 10 min, cell extracts were prepared, MAPK was speci®cally immunoprecipitated and assayed for activity as described in Materials and methods. Similar results were obtained in two additional experiments. (b) Equal numbers of 23A2 myoblasts were plated and then switched to naive DM with or without 50 mM PD 098059 or A2:H-Ras conditioned media with or without 50 mM PD 098059. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure 1 . Shown are results from one experiment which are representative of three independent experiments
The activity which inhibits skeletal myoblast dierentiation is also secreted from 23A2 myoblasts rendered dierentiation-defective by expression of oncogenic N-Ras
To determine whether this is a general consequence of oncogenic Ras expression or if the production of this inhibitory activity is restricted to the oncogenic H-Ras isoform, we tested 23A2 cell lines expressing oncogenic N-Ras. Oncogenic N-Ras inhibits the dierentiation of C2C12 myoblasts Gossett et al., 1988) but has not previously been shown to render 23A2 myoblasts dierentiation-defective. 23A2 myoblasts were stably transfected with the expression vector pIBW3 NT which contains the coding sequence for Q61K-N-Ras. After clonal selection, several lines were tested for N-Ras expression and for their ability to dierentiate. Clones 7 and 14 each express levels of N-Ras signi®cantly greater than the level of endogenous N-Ras found in the parental 23A2 control myoblasts while clone 22 expresses N-Ras at roughly the same level as that found in the parental myoblasts (Figure 8a ). Both clones 7 and 14, but not clone 22, are dierentiation-defective as monitored by the expression of MHC (Figure 8b ) and by fusion into myotubes (Figure 8c ). Coculture of 23A2 myoblasts with an equal number of A2:N-Ras clones 7 and 14 prevented the expression of MHC (Figure 9a ). Furthermore, 23A2 myoblasts cultured in DM previously conditioned by A2:N-Ras clones 7 and 14, but not clone 22, abrogated the expression of MHC (Figure 9b ).
Discussion
Deregulated proliferation and defective dierentiation are obligate events during tumorigenesis since proliferation and terminal dierentiation are ultimately An activity which inhibits skeletal myoblast differentiation is secreted by dierentiation-defective A2:N-Ras clones. (a) 23A2 myoblasts were cocultured in DM with an equal number of the indicated A2:N-Ras clone. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure 1 . (b) Equal numbers of 23A2 myoblasts were plated and then switched to DM or DM which had been previously conditioned for 48 h with the indicated cell line. After 48 h, cell extracts were prepared and a Western analysis for MHC was performed as described in Figure 1 mutually exclusive events (Visscher and Heppner, 1996) . Oncogenic mutation of ras genes has been implicated as a causative event throughout the process of tumorigenesis (Weyman and Stacey, 1996) and expression of oncogenic Ras is correlated with the secretion of both growth and angiogenic factors (Pironin et al., 1992; Dawson et al., 1995; Rak et al., 1995; Berkowitz et al., 1996) . While the signi®cance of autocrine growth factor loops to the proliferation of tumor cells is accepted dogma, the contribution of autocrine growth loops to the inhibition of differentiation has not been extensively explored. Expression of oncogenic Ras induces both a transformed and a dierentiation-defective phenotype in 23A2 myoblasts Weyman et al., 1997) . We demonstrate that A2:H-Ras or A2-N-Ras cells secrete a factor(s) which inhibits the dierentiation of 23A2 myoblasts. This data support the contention that oncogenic Ras-induced autocrine growth loops not only contribute to deregulated proliferation but also contribute to the dierentiation-defective phenotype. Furthermore, the known peptide growth factors which inhibit skeletal myoblast dierentaition were not detected in A2:H-Ras conditioned media as examined immunologically by Western analyses, biochemically by assessing MAPK activation, or biologically by assessing the inhibition of DNA synthesis in CCL64 cells. The dierentiation inhibitor secreted by oncogenic Ras expressing cells is, therefore, apparently a novel inhibitor of skeletal myoblast dierentiation. Rhabdomyosarcoma is a tumor of skeletal muscle. Cell lines derived from these tumors secrete IGF, FGF-2, EGF and TGFa. Blocking these pathways individually or in combination through the use of speci®c neutralizing antibodies inhibited proliferation but did not restore a myogenic phenotype. Blocking essentially all autocrine growth loops with suramin, a general growth factor antagonist, however, inhibited both proliferation and restored the myogenic phenotype (Giovanni et al., 1995) . The ®nding that the degree of proliferation is not inversely proportional to the degree of dierentiation is not surprising since it is well documented that the inhibition of dierentiation by growth factors or by oncogenic Ras is independent of their mitogenicity Olson et al., 1987; Payne et al., 1987; Gossett et al., 1988; Lathrop et al., 1985; Rosenthal and Cheng, 1995; Weyman et al., 1997) . It is somewhat intriguing, however, that blocking both FGF-2 and IGF does not revert the dierentiation-defective phenotype. We report here an analogous ®nding in that the activity in A2:H-Ras conditioned DM is suramin-sensitive but distinct from FGF-2, IGF-1 and TGF-b. In contrast to the report that treatment with suramin could restore the myogenic ability of rhabdomyosarcoma cell lines, suramin treatment could not revert the differentiation-defective phenotype of the A2:H-Ras cells (d.n.s.). One possible explanation for this dierence is simply that oncogenic Ras activates other pathways which are sucient for the inhibition of dierentiation. Another is provided by the ®nding that the neutralization of the inhibitory factor(s) by suramin is titratable. Suramin concentrations greater than 100 mM are toxic to both 23A2 myoblasts and A2:H-Ras cells (personal observation). 100 mM suramin can neutralize the secreted inhibitory activity at 1/10 strength but does not neutralize this activity in undiluted conditioned media (d.n.s). The toxicity limitation imposed on the concentration of suramin may not, therefore, permit neutralization of the inhibitory activity in media conditioned by the continual presence of A2:H-Ras cells over the 48 h required for the detection of initial markers of dierentiation such as MHC.
The inhibition of dierentiation by FGF-2, IGF-1, TGFb, or oncogenic Ras relies on continual signaling (Lathrop et al., 1985; Olson et al., 1986; Clegg et al., 1987; Gossett et al., 1988; Vaidya et al., 1989; Nakafuku et al., 1992) . Induction of an autocrine loop would be an ecient mechanism to ensure a continual supply of inhibitor. The ®nding that the oncogenic Ras-induced dierentiation inhibitor is distinct from FGF-2 and IGF-1, however, is consistent with previous studies from our lab reporting a distinction between the signaling pathways utilized by oncogenic Ras and both FGF-2 and IGF-1. PD 098059, a selective chemical inhibitor of the activation of MEK, and consequently the activation of MAPK, prevented the inhibition of dierentiation by FGF-2 and IGF-1 (manuscript submitted) but did not aect the dierentiation-defective phenotype established by oncogenic Ras (Weyman et al., 1997) . Also consistent with our previous ®ndings is the demonstration that DM conditioned by A2:H-Ras cells fails to activate MAPK and inhibits the dierentiation of 23A2 myoblasts similarly in the absence or presence of PD 098059. The challenge now is to determine the signaling pathway(s) activated by the oncogenic Rasinduced secreted factor(s) which is critical to the abrogation of dierentiation. This endeavor will be simpli®ed by the puri®cation and identi®cation of this putative novel inhibitor of skeletal myoblast differentiation.
Materials and methods
Reagents
The anti-MAP kinase antibody (TR10) was provided by Michael Weber (U. Va.). PD 098059 was provided by Alan Saltiel (Parke Davis). TGFb and CCL64 cells were provided by Phil Howe (CCF). The (Q61K)N-Ras expression vector pIBW3
NT was provided by A Pellicer (NYU Medical Center). FGF2 and IGF-1 were purchased from Austral Biologicals and suramin was purchased from RBI.
Cells and cell culture
The growth and dierentiation properties of 23A2 myoblasts and the 23A2 derivative expressing the human Ha-ras oncogene (A2:H-Ras cells) have been previously reported . A2:N-Ras clones were derived from 23A2 myoblasts by transfection with the expression vector pIBW3
NT encoding the sequence for Q61K-N-Ras using the lipofectamine method as per Gibco/BRL. Undierentiated, proliferating 23A2, A2:HRas, and A2:N-Ras cells were maintained in growth medium (BME supplemented with 10% FBS and 1% P/ S) at low density on gelatin coated dishes. Dierentiation was induced by treating cells with dierentiation medium (BME, 1% P/S). C3H 10T1/2 cells were cultured on nongelatinized dishes under the same conditions as the C3H10T1/2-derived 23A2 myoblast cell line. PD 098059 was dissolved in DMSO to give a ®nal concentration of 37 mM and stored at 7808C. DMSO alone (50.15% v/v) was added to control cultures.
Immunoblot analysis
Cell extracts were equalized for total cell protein, denatured by addition of Laemmli buer, resolved by SDS ± PAGE and electrophoretically transferred to immobilon P. The Immobilon P was blocked for 1 h at room temperature in 16TBS/0.1% NP40 with 1% calf serum and 5% dry milk. After washing with TBS/0.1% NP40, the Immobilon P was incubated for 1 h with MF20, a mouse monoclonal antibody speci®c for skeletal muscle myosin heavy chain (a generous gift of EJ Taparowsky, Purdue). After washing 56 with TBS/0.1% NP40 (10 min each), the immobilon P was incubated for 1 h with a rabbit antimouse secondary antibody (1 : 1000), washed as before, and incubated for another hour with 125 I-labeled goat antirabbit (5 mCi) antibody (Amersham). After washing, [
125 I] was visualized and quantitated by Phosphorimager analysis. For immunological detection of FGF-2, TGFb or N-Ras, after incubation with the appropriate primary antibody (diluted as per Santa Cruz) and washing, the blot was incubated for 45 min with the appropriate IgG conjugated to horseradish peroxidase (1 : 3000, Santa Cruz). After washing, immunoreactive bands were detected using standard enhanced chemiluminescence techniques.
Immunohistochemistry
Cells were rinsed twice with cold 16phosphate-buered saline (PBS) and ®xed for one minute with a solution of 70% ethanol:formalin:acetic acid (20 : 2 : 1). Fixed cells were permeabilized with TBS/0.1% NP40 and blocked by incubation with 2% horse serum in PBS. This was followed by incubation with the MF20 antibody, washing, incubation with a biotinylated goat anti-mouse IgG secondary antibody (1 : 300, Vector Laboratories), washing, and incubation with horseradish peroxidase streptavidin (1 : 250, Vector Laboratories). Immunoreactivity was visualized using a solution of 3,3'-diaminobenzidine (1 mg/ml), 30% H 2 O 2 (1 ml/ml) and NiCl 2 (5 mg/ml) in PBS.
MAP kinase activity assay
Cell extracts were prepared in p21 buer (20 mM MOPS pH 7.4, 4 mM magnesium chloride, 200 mM sucrose, 0.1 mM EDTA) supplemented with 1% CHAPS, protease and phosphatase inhibitors. TR10 antibody precoupled to protein A sepharose was added to extracts followed by rotation for 1 h at 48C. After sedimentation, pellets were washed three times with Tris-buered saline (TBS)/0.1% NP40 and once with p21 buer and then incubated for 20 min at 378C with 25 mM myelin basic protein (MBP), 10 mM [g-32 P]ATP (10 mCi, 44500 Ci/mol) and 10 mM phosphatase inhibitors in a total volume of 50 ml (Moodie et al., 1993) . Assays were performed within the linear range of [ 32 P] incorporation and were terminated by the addition of 26 Laemmli buer. Reaction products were separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS ± PAGE: 15%). The gel was dried and phosphorylated bands visualized and quantitated by Phosphorimager analysis.
Thymidine incorporation
Equal numbers of CCL64 cell were plated and then treated with 2 ng/ml TGFb or media conditioned for 48 h by the indicated cell line for 22 h. During the ®nal 4 h cultures were supplemented with 1 mCi/ml of [methyl-
3 H]thymidine. Cultures were washed with TBS and ®xed by two incubations with 10% trichloroacetic acid. Acid insoluble material was dissolved by the addition of 0.2 N sodium hydroxide supplemented with salmon sperm DNA carrier (40 mg/ml) and quantitated by liquid scintillation counting.
